Coherus BioSciences develops immuno-oncology therapies aimed at cancer treatment, including FDA-approved medicines such as LOQTORZI. It focuses on improving patient outcomes through a diversified pipeline of drug candidates.

Coherus BioSciences

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 2, 2024 5:19 AM	535de320
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Oct 4, 2024 8:31 AM	4ddd28e7
company summary	general
signals	general	Oct 2, 2024 5:19 AM	43594129
crunchbase trigger	general	Nov 27, 2024 12:50 PM	04e6ad66
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 2, 2024 5:19 AM	f644c093
news basic	general	Oct 2, 2024 5:19 AM	f51fc3e6
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:COHERUS

Coherus BioSciences

Last Close

1.10

22/11 21:00

Market Cap

164.06M

Beta: -

Volume Today

2.69M

Avg: -